287 related articles for article (PubMed ID: 12211720)
21. Impact of interferon-alpha therapy on the serum level of alpha-fetoprotein in patients with chronic viral hepatitis.
Kasztelan-Szczerbińska B; Słomka M; Celiński K; Szczerbiński M
Rocz Akad Med Bialymst; 2003; 48():74-7. PubMed ID: 14737946
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation of serum C3 and CH50 levels as markers of disease-activity and indicators of efficacy of treatment of lupus nephritis in childhood].
Ibe M; Kuriyama T; Mori M; Mitsuda T; Aihara Y; Yokota S
Ryumachi; 1994 Aug; 34(4):715-24. PubMed ID: 7974022
[TBL] [Abstract][Full Text] [Related]
23. Interferon treatment in children with chronic hepatitis B: an Israeli experience.
Hartman C; Hager H; Berkowitz D; Rimon N; Bassan L; Trogouboff P; Teitler A; Shamir R
Isr Med Assoc J; 2002 Nov; 4(11 Suppl):914-8. PubMed ID: 12455179
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and regulation of the fourth component of complement (C4) in the human monocytic cell line U937: comparison with that of the third component of complement (C3).
Tsukamoto H; Nagasawa K; Yoshizawa S; Tada Y; Ueda A; Ueda Y; Niho Y
Immunology; 1992 Apr; 75(4):565-9. PubMed ID: 1592431
[TBL] [Abstract][Full Text] [Related]
25. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
[TBL] [Abstract][Full Text] [Related]
26. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
[TBL] [Abstract][Full Text] [Related]
27. Liver histology of children with chronic hepatitis treated with interferon-alpha alone or in combination with lamivudine.
Kuloglu Z; Krsaçloglu CT; Kansu A; Erden E; Girgin N
J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):564-8. PubMed ID: 18030234
[TBL] [Abstract][Full Text] [Related]
28. Interferon-alfa treatment may reduce the occurrence of liver carcinogenesis in patients with chronic viral hepatitis.
Kasztelan-Szczerbińska B; Słomka M; Celiński K; Lozowski CT; Daniluk J; Szczerbiński M
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):280-5. PubMed ID: 15314999
[TBL] [Abstract][Full Text] [Related]
29. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
McHutchison JG; Shiffman ML; Cheung RC; Gordon SC; Wright TL; Pottage JC; McNair L; Ette E; Moseley S; Alam J
Antivir Ther; 2005; 10(5):635-43. PubMed ID: 16152757
[TBL] [Abstract][Full Text] [Related]
30. IFN-gamma up-regulates expression of the complement components C3 and C4 by stabilization of mRNA.
Mitchell TJ; Naughton M; Norsworthy P; Davies KA; Walport MJ; Morley BJ
J Immunol; 1996 Jun; 156(11):4429-34. PubMed ID: 8666817
[TBL] [Abstract][Full Text] [Related]
31. Presence of HCV RNA in hepatic tissue and effectiveness of treatment with interferon and ribavirin.
Lakomy EA; Bielawski KP; Sikorska K; Stalke P; Michalska Z; Witczak-Malinowska K
Med Sci Monit; 2003 Aug; 9 Suppl 3():36-8. PubMed ID: 15156610
[TBL] [Abstract][Full Text] [Related]
32. [CH50, C3 and C4 in the serum and synovial fluid of rheumatoid arthritis patients].
Sheĭtanov I; Nikolov K; Petrova P
Vutr Boles; 1987; 26(4):66-70. PubMed ID: 3499707
[TBL] [Abstract][Full Text] [Related]
33. Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy.
Hamamoto S; Uchida Y; Wada T; Moritani M; Sato S; Hamamoto N; Ishihara S; Watanabe M; Kinoshita Y
J Gastroenterol Hepatol; 2005 Feb; 20(2):204-8. PubMed ID: 15683422
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
35. Sustained response with negative serum HCV-mRNA and disappearance of antibodies after interferon-alpha therapy in a kidney transplant recipient with chronic active viral hepatitis C.
Luciani G; Bossola M; Muscaritoli M; Panocchia N; Ferrante A; Nanni G; Piccioni E; Tazza L; Grillo RL; Rossi Fanelli F; Castagneto M
J Nephrol; 2003; 16(3):417-20. PubMed ID: 12832744
[TBL] [Abstract][Full Text] [Related]
36. Total hemolytic complement (CH50) and its fractions (C3 and C4) in the sera of patients with premalignant and malignant lesions of the oral cavity.
Rajendran R; Remani P; Vijayakumar T; Vasudevan DM
Ann Dent; 1990; 49(1):36-8, 51. PubMed ID: 2346298
[TBL] [Abstract][Full Text] [Related]
37. [Complement C3 and C4 levels in serum from acute viral hepatitis].
Ozer FT; Barut A; Inal A; Hacibektaşoğlu A
Mikrobiyol Bul; 1992 Oct; 26(4):314-9. PubMed ID: 1435361
[TBL] [Abstract][Full Text] [Related]
38. Complement C4 monitoring in the follow-up of chronic hepatitis C treatment.
Dumestre-Perard C; Ponard D; Drouet C; Leroy V; Zarski JP; Dutertre N; Colomb MG
Clin Exp Immunol; 2002 Jan; 127(1):131-6. PubMed ID: 11882043
[TBL] [Abstract][Full Text] [Related]
39. [The assessment of nutritional status in children with chronic hepatitis B treated with interferon alpha].
Lebensztejn DM; Zagórecka E; Kaczmarski M; Piotrowska-Jastrzebska J
Pol Merkur Lekarski; 2001 Jul; 11(61):29-31. PubMed ID: 11579826
[TBL] [Abstract][Full Text] [Related]
40. Differential cytokine regulation of complement C3, C4, and factor B synthesis in human intestinal epithelial cell line, Caco-2.
Andoh A; Fujiyama Y; Bamba T; Hosoda S
J Immunol; 1993 Oct; 151(8):4239-47. PubMed ID: 8409399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
